|
gptkbp:instanceOf
|
gptkb:drug
stimulant
|
|
gptkbp:affiliatedWith
|
amphetamine
|
|
gptkbp:ATCCode
|
N06BA02
|
|
gptkbp:brand
|
gptkb:Dexedrine
gptkb:Dextrostat
gptkb:ProCentra
gptkb:Zenzedi
|
|
gptkbp:CASNumber
|
51-64-9
|
|
gptkbp:chemicalFormula
|
C9H13N
|
|
gptkbp:contraindication
|
gptkb:cardiovascular_disease
glaucoma
hyperthyroidism
history of drug abuse
|
|
gptkbp:discoveredBy
|
gptkb:Gordon_Alles
|
|
gptkbp:discoveredIn
|
1929
|
|
gptkbp:eliminationHalfLife
|
10-12 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasEnantiomer
|
amphetamine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
dextroamphetamine
|
|
gptkbp:isomerOf
|
gptkb:levoamphetamine
|
|
gptkbp:IUPACName
|
(S)-1-phenylpropan-2-amine
|
|
gptkbp:legalStatus
|
Schedule II controlled substance (US)
|
|
gptkbp:mechanismOfAction
|
increases synaptic concentrations of dopamine and norepinephrine
|
|
gptkbp:meltingPoint
|
129-130°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
135.21 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescriptionStatus
|
prescription only (US)
|
|
gptkbp:PubChem_CID
|
5826
CHEMBL1201207
DB01576
|
|
gptkbp:riskFactor
|
hypertension
psychosis
sudden cardiac death
potential for abuse
dependence
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
anxiety
loss of appetite
increased heart rate
insomnia
dry mouth
|
|
gptkbp:solubility
|
soluble in water
|
|
gptkbp:synonym
|
(S)-amphetamine
d-amphetamine
|
|
gptkbp:UNII
|
PO5U3187Z5
|
|
gptkbp:usedFor
|
gptkb:attention_deficit_hyperactivity_disorder
narcolepsy
|
|
gptkbp:bfsParent
|
gptkb:Adderall
gptkb:Amphetamine
gptkb:amphetamine
|
|
gptkbp:bfsLayer
|
6
|